N. Bose

发表

Secretory products of breast cancer cells upregulate hyaluronan production in a human osteoblast cell line

N. Bose, A. Masellis, 2006, Clinical & Experimental Metastasis.

Differential regulation of oxidative burst by distinct β-glucan-binding receptors and signaling pathways in human peripheral blood mononuclear cells.

F. Lebeda, N. Bose, J. Vasilakos, 2014, Glycobiology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

General Perspectives of Homeopathic Medicine During the First and Second Trimesters of Pregnancy

Sushanta K Banerjee, N. Bose, N. Bhattacharya, 2016 .

Ayurvedic Perspective of Pregnancy and Fetal Development During the First and Second Trimester

Sushanta K Banerjee, N. Bose, N. Bhattacharya, 2016 .

Inhibitory affinity modulation of FcγRIIA ligand binding by glycosphingolipids by inside-out signaling

T. Mayadas, X. Cullere, Cheng Zhu, 2021, Cell reports.

Crystallization and preliminary X-ray crystallographic studies of recombinant human betaine-homocysteine S-methyltransferase.

N. Bose, C. Momany, 2001 .

Structural and Functional Developmental Perspectives of the Placental Barrier and Its Role in the Fetal Development During the First and Second Trimesters

Sushanta K Banerjee, N. Bose, S. Tripathi, 2016 .

Crystal and Molecular Structure of tetrakis(4-Methylpyridine)nickel(II)perchlorate, [Ni(II)(C6H7N)4][ClO4]2

N. Bose, H. Lynton, 1973 .

Activation of the innate immune receptor Dectin-1 upon formation of a “phagocytic synapse”

Jun Ma, Arthur Weiss, John P. Vasilakos, 2011, Nature.

Fetus as a Patient During the First and Second Trimesters of Growth and Development

N. Bose, N. Bhattacharya, Priyodarshi Sengupta, 2016 .

Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent

N. Bose, J. Vasilakos, A. Chan, 2013, Front. Immunol..

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer

J. Marier, F. Schneller, M. Thomas, 2017, Investigational New Drugs.

Imprime PGG Enhances Anti-Tumor Effects of Tumor-Targeting, Anti-Angiogenic, and Immune Checkpoint Inhibitor Antibodies

J. Graff, M. Uhlik, N. Bose, 2022, Frontiers in Oncology.

Immunoglobulin Restores Immune Responses to BTH1677 in Patients With Low Levels of Antibodies to Beta-glucan

N. Bose, A. Dudek, Xiaohong X. Qiu, 2020, AntiCancer Research.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Imprime PGG-Mediated Anti-Cancer Immune Activation Requires Immune Complex Formation

J. Graff, N. Bose, A. Chan, 2016, PloS one.

Immune Pharmacodynamic Responses of the Novel Cancer Immunotherapeutic Imprime PGG in Healthy Volunteers

J. Graff, M. Uhlik, Kathryn A. Fraser, 2019, The Journal of Immunology.

Abstract LB-129: Imprime PGG, a soluble yeast β-glucan PAMP, in combination with Pembrolizumab induces infiltration and activation of both innate and adaptive immune cells within tumor sites in melanoma and triple-negative breast cancer (TNBC) patients

J. Graff, M. Uhlik, B. Osterwalder, 2018, Immunology.

Abstract LB-089: Imprime PGG, a β-glucan PAMP (pathogen-associated molecular pattern), effectively elicits in vivo maturation of antigen presenting cells in mice and humans, suggesting potential synergy with checkpoint inhibitor therapy

J. Graff, Kathryn A. Fraser, N. Bose, 2016 .

Recognition of soluble yeast β-1,3/1,6 glucan by complement receptor 1 is essential for it to bind complement receptor 3 on human neutrophils and monocytes, and complement receptor 2 on B cells (P3048)

N. Bose, A. Chan, Xiaohong X. Qiu, 2013, Journal of Immunology.

Imprime PGG, a yeast β-glucan immunomodulator, has the potential to repolarize human monocyte-derived M2 macrophages to M1 phenotype

N. Bose, A. Chan, M. Patchen, 2014, Journal of Immunotherapy for Cancer.

Expression of recombinant human betaine: homocysteine S-methyltransferase for x-ray crystallographic studies and further characterization of interaction with S-adenosylmethionine.

N. Bose, P. Greenspan, C. Momany, 2002, Protein expression and purification.

American Association of Immunologists Recommendations for an Undergraduate Course in Immunology

A. Bottaro, J. Jameson, S. Varga, 2021, ImmunoHorizons.

Abstract PD1-02: Response and clinical benefit assessment of the combination of the dectin-1 agonist imprime PGG and anti-PD-1 pembrolizumab in chemotherapy-resistant metastatic triple negative breast cancer (TNBC)

A. Stopeck, V. Borges, J. Graff, 2020 .

Abstract LB-225: Imprime PGG modulates the function of monocyte-derived M2 macrophages and dendritic cells to drive T-cell expansion

N. Bose, A. Chan, Xiaohong X. Qiu, 2015 .

Abstract LB-228: Imprime PGG treatment elicits a coordinated antitumor immune response that triggers enhanced expression of PD-L1 on tumor cells as well as monocyte-derived macrophages and dendritic cells

J. Graff, N. Bose, A. Chan, 2015 .

General Perspectives and Applications of Unani Medicine in Pregnancy Up to the 2nd Trimester

N. Bose, N. Bhattacharya, Priyodarshi Sengupta, 2016 .

Endogenous anti-β-glucan antibodies as a potential predictive biomarker for clinical response to imprime PGG immunotherapy in non-small cell lung cancer (NSCLC) patients.

Michael Thomas, F. Schneller, D. McMurray, 2014 .

Abstract A015: Imprime PGG treatment enhances antibody-dependent cellular phagocytosis (ADCP) of tumor cells by monocyte-derived macrophages

J. Graff, N. Bose, A. Chan, 2016 .

Rapid Cloning For Protein Crystallography Using Type IIS Restriction Enzymes

N. Bose, Cory Momany, C. Momany, 2013 .

Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice

M. Uhlik, N. Bose, G. Beatty, 2023, Nature communications.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Imprime PGG, an innate immunomodulator for cancer immunotherapy has the potential to modulate macrophages in the tumor and the spleen to an anti-tumor M1-like phenotype

J. Graff, Xiahong Qiu, Kathryn A. Fraser, 2015, Journal of Immunotherapy for Cancer.